JP2025509088A5 - - Google Patents
Info
- Publication number
- JP2025509088A5 JP2025509088A5 JP2024548556A JP2024548556A JP2025509088A5 JP 2025509088 A5 JP2025509088 A5 JP 2025509088A5 JP 2024548556 A JP2024548556 A JP 2024548556A JP 2024548556 A JP2024548556 A JP 2024548556A JP 2025509088 A5 JP2025509088 A5 JP 2025509088A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- compound
- pharmaceutically acceptable
- nlrp3
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263311463P | 2022-02-18 | 2022-02-18 | |
| US63/311,463 | 2022-02-18 | ||
| PCT/US2022/075421 WO2023028534A1 (en) | 2021-08-25 | 2022-08-24 | Inhibitors of nlrp3 |
| USPCT/US2022/075421 | 2022-08-24 | ||
| PCT/US2023/062771 WO2023159148A2 (en) | 2022-02-18 | 2023-02-16 | Inhibitors of nlrp3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025509088A JP2025509088A (ja) | 2025-04-11 |
| JP2025509088A5 true JP2025509088A5 (https=) | 2026-02-25 |
Family
ID=87579158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024548556A Pending JP2025509088A (ja) | 2022-02-18 | 2023-02-16 | Ｎｌｒｐ３の阻害剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250179078A1 (https=) |
| EP (1) | EP4479045A4 (https=) |
| JP (1) | JP2025509088A (https=) |
| KR (1) | KR20240164495A (https=) |
| CN (2) | CN118302417A (https=) |
| AU (1) | AU2023221847A1 (https=) |
| CA (1) | CA3243870A1 (https=) |
| CL (1) | CL2024002455A1 (https=) |
| CO (1) | CO2024011162A2 (https=) |
| CR (1) | CR20240345A (https=) |
| IL (1) | IL315027A (https=) |
| MX (1) | MX2024010092A (https=) |
| PE (1) | PE20250604A1 (https=) |
| WO (1) | WO2023159148A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4362946A4 (en) * | 2021-06-29 | 2025-05-21 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| WO2023051761A1 (zh) * | 2021-09-30 | 2023-04-06 | 成都奥睿药业有限公司 | 一类取代杂芳酞嗪衍生物的药学用途及其制备方法 |
| JP2025524640A (ja) * | 2022-07-14 | 2025-07-30 | エーシー・イミューン・エス・アー | Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体 |
| CN120379995A (zh) * | 2022-12-27 | 2025-07-25 | 正大天晴药业集团股份有限公司 | 一种哒嗪稠芳环化合物及其用途 |
| EP4667468A1 (en) | 2023-02-14 | 2025-12-24 | Shenzhen Zhongge Biological Technology Co., Ltd. | Compound for inhibiting nlrp3, preparation method, and use |
| US20250195511A1 (en) * | 2023-12-14 | 2025-06-19 | Merck Sharp & Dohme Llc | Indazole derivatives useful as inhibitors of nod-like receptor protein 3 |
| WO2025133307A1 (en) * | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Heterocyclic modulators of the nlrp3 inflammasome pathway |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2026057747A1 (en) | 2024-09-11 | 2026-03-19 | Ac Immune Sa | Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds |
| WO2026067767A1 (zh) * | 2024-09-30 | 2026-04-02 | 普罗思特(南京)生物科技有限公司 | 取代的哒嗪衍生物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ702611A (en) * | 2012-05-16 | 2016-10-28 | Cellzome Ltd | Substituted 3, 4 - dihydro - 2h - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) alzheimer’s disease |
| WO2014007217A1 (ja) * | 2012-07-02 | 2014-01-09 | 大鵬薬品工業株式会社 | イミダゾオキサジン化合物による抗腫瘍効果増強剤 |
| WO2018221433A1 (ja) * | 2017-05-29 | 2018-12-06 | 第一三共株式会社 | ヘテロアリールアミン誘導体 |
| AU2021257619A1 (en) * | 2020-04-15 | 2022-12-15 | Janssen Pharmaceutica Nv | Pyrazolo[1,5-d][1,2,4]triazine-5(4H)-acetamides as inhibitors of the NLRP3 inflammasome pathway |
| EP4362946A4 (en) * | 2021-06-29 | 2025-05-21 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| CR20240093A (es) * | 2021-08-25 | 2024-05-23 | Ptc Therapeutics Inc | Inhibidores de NLRP3 |
| WO2023051761A1 (zh) * | 2021-09-30 | 2023-04-06 | 成都奥睿药业有限公司 | 一类取代杂芳酞嗪衍生物的药学用途及其制备方法 |
-
2022
- 2022-08-24 CN CN202280071320.9A patent/CN118302417A/zh active Pending
-
2023
- 2023-02-16 CN CN202380034776.2A patent/CN119212699A/zh active Pending
- 2023-02-16 AU AU2023221847A patent/AU2023221847A1/en active Pending
- 2023-02-16 US US18/839,229 patent/US20250179078A1/en active Pending
- 2023-02-16 IL IL315027A patent/IL315027A/en unknown
- 2023-02-16 WO PCT/US2023/062771 patent/WO2023159148A2/en not_active Ceased
- 2023-02-16 EP EP23757102.1A patent/EP4479045A4/en active Pending
- 2023-02-16 PE PE2024001809A patent/PE20250604A1/es unknown
- 2023-02-16 CR CR20240345A patent/CR20240345A/es unknown
- 2023-02-16 CA CA3243870A patent/CA3243870A1/en active Pending
- 2023-02-16 KR KR1020247027203A patent/KR20240164495A/ko active Pending
- 2023-02-16 JP JP2024548556A patent/JP2025509088A/ja active Pending
-
2024
- 2024-08-15 CL CL2024002455A patent/CL2024002455A1/es unknown
- 2024-08-16 MX MX2024010092A patent/MX2024010092A/es unknown
- 2024-08-16 CO CONC2024/0011162A patent/CO2024011162A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025509088A5 (https=) | ||
| US10898471B2 (en) | Methods of inhibiting leukotriene A4 hydrolase | |
| JP2007517059A5 (https=) | ||
| WO1995019770A1 (en) | Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex | |
| JP2023508469A5 (https=) | ||
| JP2010524953A5 (https=) | ||
| JP2022502500A5 (https=) | ||
| CA2530381C (fr) | Association d'un antagoniste ou agoniste inverse du recepteur h3 de l'histamine avec un anti-psychotique ou un antidepresseur et son utilisation pour preparer un medicament prevenant des effets indesirables de medicaments psychotropes | |
| CA2386297A1 (en) | Bicyclic amino acids as pharmaceutical agents | |
| JP7631572B2 (ja) | デューテトラベナジンの類似体、その調製及び使用 | |
| JP6426302B2 (ja) | ３−［（ベンゾ［ｄ］［１，３］ジオキソラン−４−イル）−オキシ］−３−アリールプロピルアミン型化合物およびその適用 | |
| CA2458544A1 (en) | Crystals of hydroxynorephedrine derivative | |
| FR2850023A1 (fr) | Medicaments pour le systeme nerveux | |
| US20090170954A1 (en) | Process for Recovering Florfenicol and Florfenicol Analogs | |
| JP2022505471A5 (https=) | ||
| JP2024519079A5 (https=) | ||
| RS64304B1 (sr) | Betahistin, ili njegova farmaceutski prihvatljiva so, i inhibitor monoaminske oksidaze, za upotrebu u lečenju ili prevenciji jednog ili više simptoma vrtoglavice kod subjekta | |
| JP2022508167A5 (https=) | ||
| JP5904997B2 (ja) | 神経細胞のアポトーシス又は神経変性を阻害するための医薬組成物 | |
| WO1995010269A1 (en) | Treatment of urinary incontinence and other disorders with r-terodiline and hydroxylated derivatives thereof | |
| CN117205168B (zh) | 一种低n-亚硝基普萘洛尔杂质含量的盐酸普萘洛尔片及其制备方法 | |
| TW201028155A (en) | New combination of active ingredients containing a non steroidal anti inflammatory drug and a colchicoside derivative | |
| JP2003523995A5 (https=) | ||
| JP2002541192A (ja) | Ｓ−ヒドロキシネファゾドン | |
| JP2002541191A (ja) | Ｒ−ヒドロキシネファゾドン |